Author: Vu, Christine A.; DeRonde, Kailynn J.; Vega, Ana D.; Maxam, Meshell; Holt, Gregory; Natori, Yoichiro; Zamora, Jose Gonzales; Salazar, Veronica; Boatwright, Renata; Morris, Stephen R.; de Lima Corvino, Daniela; Betances, Anmary Fernandez; Colucci, Leah; Keegan, James; Lopez, Andy; Rezk, Andrew Hany; Rodriguez, Yvette; Moraru, Gabriela M.; Doblecki, Susanne; De La Zerda, David J.; Abbo, Lilian M.
Title: Effects of Tocilizumab in COVID-19 patients: a cohort study Cord-id: n6yxusaq Document date: 2020_12_22
ID: n6yxusaq
Snippet: BACKGROUND: Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure from SARS-CoV-2. METHODS: A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020. RESULTS: Most patients were male
Document: BACKGROUND: Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure from SARS-CoV-2. METHODS: A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020. RESULTS: Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age of 54 years. Tocilizumab was administered at a median of 8 days (range 1–21) after initial symptoms and 2 days (range 0–12) after hospital admission. Within 30 days from receiving tocilizumab, 36 patients (60.0%) demonstrated clinical improvement, 9 (15.0%) died, 33 (55.0%) were discharged alive, and 18 (30.0%) remained hospitalized. Successful extubation occurred in 13 out of 29 patients (44.8%). Infectious complications occurred in 16 patients (26.7%) at a median of 10.5 days. After tocilizumab was administered, there was a slight increase in PaO(2)/FiO(2) and an initial reduction in CRP, but this effect was not sustained beyond day 10. CONCLUSIONS: Majority of patients demonstrated clinical improvement and were successfully discharged alive from the hospital after receiving tocilizumab. We observed a rebound effect with CRP, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the early treatment of COVID-19, however larger randomized controlled studies are needed to confirm this. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-020-05701-4.
Search related documents:
Co phrase search for related documents- absolute neutrophil count and additional file: 1, 2
- absolute neutrophil count and lung injury: 1
- absolute neutrophil count and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49
- absolute neutrophil count and lymphocyte neutrophil troponin: 1
- acute ards respiratory distress syndrome and additional file: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and low dose receive: 1
- acute ards respiratory distress syndrome and low incidence: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and lung autopsy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- acute ards respiratory distress syndrome and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- acute ards respiratory distress syndrome cause and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute cytokine release syndrome and additional file: 1
- acute cytokine release syndrome and lung injury: 1, 2, 3
- acute cytokine release syndrome and lymphocyte neutrophil: 1
- additional file and low dose receive: 1
- additional file and lung injury: 1, 2, 3, 4, 5, 6
- additional file and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6
- additional study and low incidence: 1
Co phrase search for related documents, hyperlinks ordered by date